DOCSLIB.ORG

Menstrually Related and Nonmenstrual Migraines in A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Menstrually Related and Nonmenstrual Migraines in A MENSTRUALLY RELATED AND NONMENSTRUAL MIGRAINES IN A FREQUENT MIGRAINE POPULATION: FEATURES, CORRELATES, AND ACUTE TREATMENT DIFFERENCES A dissertation presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Doctor of Philosophy Brenda F. Pinkerman March 2006 This dissertation entitled MENSTRUALLY RELATED AND NONMENSTRUAL MIGRAINES IN A FREQUENT MIGRAINE POPULATION: FEATURES, CORRELATES, AND ACUTE TREATMENT DIFFERENCES by BRENDA F. PINKERMAN has been approved for the Department of Psychology and the College of Arts and Sciences by Kenneth A. Holroyd Distinguished Professor of Psychology Benjamin M. Ogles Interim Dean, College of Arts and Sciences PINKERMAN, BRENDA F. Ph.D. March 2006. Clinical Psychology Menstrually Related and Nonmenstrual Migraines in a Frequent Migraine Population: Features, Correlates, and Acute Treatment Differences (307 pp.) Director of Dissertation: Kenneth A. Holroyd This research describes and compares menstrually related migraines as defined by recent proposed guidelines of the International Headache Society (IHS, 2004) to nonmenstrual migraines in a population of female migraineurs with frequent, disabling migraines. Migraines are compared by frequency per day of the menstrual cycle, headache features, use of abortive and rescue medications, and acute migraine treatment outcomes. In addition, this study explores predictors of acute treatment response and headache recurrence within 24 hours following acute migraine treatment for menstrually related migraines. Participants are 107 menstruating female migaineurs who met IHS (2004) proposed criteria for menstrually related migraines and completed headache diaries using hand-held computers. Diary data are analyzed using repeated measures logistic regression. The frequency of migraines is significantly increased during the perimenstrual period, and menstrually related migraines are of longer duration and greater frequency with longer lasting disability than nonmenstrual migraines. Participants report using more doses of triptans and rescue medication for menstrually related migraines than for migraines occurring at other times during the month. A pain- free response at two hours after acute treatment is half as likely with menstrually related than with nonmenstrual migraines (6.7% vs. 13.4%, OR .45, 95% CI .26-.80). Following a four hour pain-free response, menstrually related migraines are twice as likely to recur within 24 hours as nonmenstrual migraines (36.0% vs. 19.6%, OR 2.12, 95% CI 1.27- 3.53). In addition, birth control medication use is associated with a higher proportion of migraine recurrences (38.6%) after pain-free within 24 hours after initial dosing of acute medication than non-use [22.7%; �2 (1, 107) = 4.97, p=.026]. Pain-free response and headache recurrence is not associated with psychological or gynecological variables. However, use of rescue medication is associated with greater pain catrastrophizing and lack of reproductive event influences on migraines. This research indicates that menstrually related migraines are different from and have less favorable acute treatment outcomes than nonmenstrual attacks. Thus, these findings support the separate diagnostic classification of menstrually related migraine as proposed by the IHS (2004). Approved: Kenneth A. Holroyd Distinguished Professor of Psychology Acknowledgments First, I would like to express my gratitude to Kenneth Holroyd, Ph.D., for providing guidance and support throughout the dissertation process. He possesses a tremendous talent for being able to focus and shape ideas into a final product that is both relevant and comprehensible. He has been responsive with timely and helpful comments and suggestions to improve the overall quality of this research even during periods of personal adversity. Even more importantly, I appreciate his willingness to mentor me by providing me with encouragement and the opportunity to interact with and learn from him over the past several years. Second, I wish to thank Bernadette Heckman, Ph.D., for her role in providing me with emotional support and the wisdom of her experiences. She is a wonderful role model, both professionally and personally. She embodies the spirit of a true scientist- practitioner, and it was a privilege to work with her in the Headache Treatment and Research Project. I have appreciated her assistance in traversing the internship and postdoctoral experience. I also wish to thank the remainder of my committee, Christopher France, Ph.D., Timothy Heckman, Ph.D., and Anne Loucks, Ph.D., for giving of their time and expertise. Each of these committee members was helpful in directing this project and providing insights that guided and challenged my ideas. The overall quality of this project is significantly greater because of their input. I am indebted to the patients who shared their time and information and the numerous administrators and staff members of the Ohio University Headache Treatment and Research Project for assistance in collecting data for this project. Without the cooperation and assistance from the following people, this research could not have taken place: Connie Cottrell, Donna Shiels, Jana Drew, Gregg Tkachuk, Linda Kaufman, Sharon Waller, Raquelle Echelberger, Bernadette Heckman, Carol Nogrady, Kathleen Romenek, Kimberly Hill, Suzanne Smith, and Jessica Gibson. As my graduate education draws to a close, I also wish to thank my family for their love and sacrifices during my years of graduate education in Clinical Psychology. I thank them for sharing my trials and triumphs during this time. I especially thank my husband, Morgan Pinkerman, for his unfailing belief in my ability to succeed. 7 TABLE OF CONTENTS Page ABSTRACT 3 ACKNOWLEDGMENTS 5 LIST OF TABLES 11 LIST OF FIGURES 14 INTRODUCTION 15 Migraine Diagnosis and Epidemiology 17 Migraine Impact on Women 26 Reproductive Events and Migraine in Women 28 Menstruation and Headaches 29 Pregnancy and Migraine 35 Postpartum and Migraine 38 Menopause and Migraine 39 Exogenous Hormines and Migraine 40 Oral contraceptives 40 Hormone therapy 43 Comparison of Menstrually Related and Nonmenstrual Migraines 44 Migraine Pathophysiology and Menstrually Related Migraines 44 Neurochemicals and Migraine Pathophysiology: An Overview 46 Estrogen and Menstrual Migraine Pathogenesis 49 Headache Features and Menstrually Related Migraine 57 Acute Treatment and Menstrually Related Migraines 64 Overview of Acute Migraine Treatment 64 Nonsteroidal Antiinflammatory Drugs (NSAIDS), Combination 66 Analgesics, and Menstrual Migraines Triptans and Menstrually Related Migraines 71 NSAIDS and Triptans: Comparison and Combination 78 8 TABLE OF CONTENTS: continued Acute Migraine Treatment Response and Recurrence 83 Acute Treatment Response 85 Response and Psychological Factors 85 Response and Gynecologic Factors 87 Recurrence Following Acute Treatment 89 Summary and Overview of Present Study 90 METHOD 93 Participants 93 Procedure 106 Measures 109 Eligibility Assessment Measures 109 Structured Headache Interview 109 Migraine Disability Assessment 109 Beck Depression Inventory II 112 Primary Care Evaluation for Mental Disorders 114 Outcome Measure 115 Hand-held Computer Headache Diary 115 Treatment Response and Recurrence Predictor Measures 117 Gynecological History: Long and Short Forms 118 Migraine-Specific Quality of Life Questionnaire 122 Pain Catastrophizing Scale 124 Statistical Analysis 126 Power Analysis 132 RESULTS 133 Prevalence of Headache per Day of the Menstrual Cycle 133 Comparison of Menstrually Related and Nonmenstrual Migraines 135 Headache Features 135 Medication Use per Migraine 142 Acute Treatment Outcomes 146 9 TABLE OF CONTENTS: continued Birth Control Medication and Menstrually Related Migraines 151 Prevalence of Migraines Across the Menstrual Cycle 154 Headache Features 156 Medication Use per Migraine 159 Acute Treatment Outcomes 162 Exploratory Analyses: Predictors of Response and Headache Recurrence Following Acute Treatment of Migraines 166 DISCUSSION 176 Summary of Findings 177 Comparison to Previous Findings 178 Frequency of Menstrually Related Migraines 178 Headache Features of Menstrually Related Migraines 180 Use of Abortive and Rescue Medications per Migraine 184 Acute Migraine Treatment Outcomes 186 Exploratory Analyses: Predictors of Response and Headache Recurrence 192 Implications of Findings 195 Limitations of the Study 198 Future Directions 199 Conclusions 203 REFERENCES 205 APPENDICES 251 Appendix A Handheld Electronic Headache Diary Instructions 251 Appendix B Beck Depression Inventory-II 254 Appendix C Gynecological History, Long Form 259 Appendix D Gynecological History, Short Form 267 10 TABLE OF CONTENTS: continued Appendix E Migriane-Specific Quality of Life Questionnaire 271 Appendix F Pain Catastrophizing Scale 276 Appendix G TSM-Human Subjects Informed Consent Form: Assessment 277 & Treatment Phase Appendix H TSM-Human Subjects Informed Consent Form: Evaluation 283 Phase Appendix I Structured Headache Interview 286 Appendix J TSM Treatment Decision Protocol 290 Appendix K Primary Care Evaluation for Mental Disorders 294 Appendix L Patient Handout on Frequently Asked Medication Questions 301 Appendix M Summary of Repeated Measures Logistic Regression for 306 Anxiety and Depressive Symptoms with Treatment Outcomes 11 LIST OF TABLES Table Page 1. International Headache Society Diagnostic Criteria for Migraine without Aura 19 2. International Headache Society Diagnostic
Load more

Recommended publications
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Use of Analgesics in Exotic Felids Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University Of
    Use of Analgesics in Exotic Felids Formatted: Centered Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University of Tennessee, and Consulting Veterinarian, Knoxville Zoological Gardens, Knoxville, Tennessee. Corresponding address: Ed Ramsay Dept. of Sm Animal Clin Sci C247, Veterinary Teaching Hospital University of Tennessee Knoxville, TN 37996-4544 Phone: 865-755-8219 FAX: 865-974-5554 Email: [email protected] 2 Treatment of pain in domestic and non-domestic cats has been a challenge for the clinician. Many cat species are stoic and show few or very subtle external signs of pain. Additionally, the adverse effects of nonsteroidal antiinflammatory drugs (NSAIDs) in domestic cats are well documented and have discouraged many practitioners from trying novel NSAID’s in exotic felids. As in other animals, each cat’s response to pain and analgesics will vary, necessitating an individualized treatment plan. As a rule, always treat painful felids to effect, and not by rote reliance on published dosages. It is frequently necessary to try different agents and combinations to find which produces the optimal analgesic effect in exotic felids. In order to minimize adverse effects, it is desirable to work toward treatment with the lowest effective dose when treating chronic pain. Non-steroidal Antiinflammatory Drugs NSAIDs are antiinflammatory drugs which act both centrally and peripherally. The primary effects are believed to be caused by their ability to inhibit cyclooxygenase (COX) enzymes in the arachidonic acid metabolism cascade. The COX-1 isoform is regarded as constitutive (continuously expressed) and is responsible for many homeostatic processes, such as maintenance of gastric mucosal integrity, platelet function, and renal autoregulation.
    [Show full text]
  • Acute Migraine Treatment
    Acute Migraine Treatment Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA Mo Levin Disclosures Consulting Royalties Allergan Oxford University Press Supernus Anadem Press Amgen Castle Connolly Med. Publishing Lilly Wiley Blackwell Mo Levin Disclosures Off label uses of medication DHE Antiemetics Zolmitriptan Learning Objectives At the end of the program attendees will be able to 1. List all important options in the acute treatment of migraine 2. Discuss the evidence and guidelines supporting the major migraine acute treatment options 3. Describe potential adverse effects and medication- medication interactions in acute migraine pharmacological treatment Case 27 y/o woman has suffered ever since she can remember from “sick headaches” . Pain is frontal, increases over time and is generally accompanied by nausea and vomiting. She feels depressed. The headache lasts the rest of the day but after sleeping through the night she awakens asymptomatic 1. Diagnosis 2. Severe Headache relief Diagnosis: What do we need to beware of? • Misdiagnosis of primary headache • Secondary causes of headache Red Flags in HA New (recent onset or change in pattern) Effort or Positional Later onset than usual (middle age or later) Meningismus, Febrile AIDS, Cancer or other known Systemic illness - Neurological or psych symptoms or signs Basic principles of Acute Therapy of Headaches • Diagnose properly, including comorbid conditions • Stratify therapy rather than treat in steps • Treat early
    [Show full text]
  • Migraine: Spectrum of Symptoms and Diagnosis
    KEY POINT: MIGRAINE: SPECTRUM A Most patients develop migraine in the first 3 OF SYMPTOMS decades of life, some in the AND DIAGNOSIS fourth and even the fifth decade. William B. Young, Stephen D. Silberstein ABSTRACT The migraine attack can be divided into four phases. Premonitory phenomena occur hours to days before headache onset and consist of psychological, neuro- logical, or general symptoms. The migraine aura is comprised of focal neurological phenomena that precede or accompany an attack. Visual and sensory auras are the most common. The migraine headache is typically unilateral, throbbing, and aggravated by routine physical activity. Cutaneous allodynia develops during un- treated migraine in 60% to 75% of cases. Migraine attacks can be accompanied by other associated symptoms, including nausea and vomiting, gastroparesis, di- arrhea, photophobia, phonophobia, osmophobia, lightheadedness and vertigo, and constitutional, mood, and mental changes. Differential diagnoses include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoenphalopathy (CADASIL), pseudomigraine with lymphocytic pleocytosis, ophthalmoplegic mi- graine, Tolosa-Hunt syndrome, mitochondrial disorders, encephalitis, ornithine transcarbamylase deficiency, and benign idiopathic thunderclap headache. Migraine is a common episodic head- (Headache Classification Subcommittee, ache disorder with a 1-year prevalence 2004): of approximately 18% in women, 6% inmen,and4%inchildren.Attacks Recurrent attacks of headache, consist of various combinations of widely varied in intensity, fre- headache and neurological, gastrointes- quency, and duration. The attacks tinal, and autonomic symptoms. Most are commonly unilateral in onset; patients develop migraine in the first are usually associated with an- 67 3 decades of life, some in the fourth orexia and sometimes with nausea and even the fifth decade.
    [Show full text]
  • Hormonal Contraceptive Treatment May Reduce the Risk of Fibromyalgia in Women with Dysmenorrhea: a Cohort Study
    Journal of Personalized Medicine Article Hormonal Contraceptive Treatment May Reduce the Risk of Fibromyalgia in Women with Dysmenorrhea: A Cohort Study Cheng-Hao Tu 1,* , Cheng-Li Lin 2, Su-Tso Yang 3,4, Wei-Chih Shen 5,6 and Yi-Hung Chen 1,7,8,* 1 Graduate Institute of Acupuncture Science, China Medical University, Taichung 404333, Taiwan 2 Management Office for Health Data, China Medical University Hospital, Taichung 404332, Taiwan; [email protected] 3 Department of Medical Imaging, China Medical University Hospital, Taichung 404332, Taiwan; [email protected] 4 School of Chinese Medicine, China Medical University, Taichung 404333, Taiwan 5 Center of Augmented Intelligence in Healthcare, China Medical University Hospital, Taichung 404332, Taiwan; [email protected] 6 Department of Computer Science and Information Engineering, Asia University, Taichung 413305, Taiwan 7 Traditional Chinese Medicine Research Center, China Medical University, Taichung 404333, Taiwan 8 Department of Photonics and Communication Engineering, Asia University, Taichung 41354, Taiwan * Correspondence: [email protected] (C.-H.T.); [email protected] (Y.-H.C.); Tel.: +886-4-22053366 (C.-H.T.) (ext. 3336) Received: 17 November 2020; Accepted: 11 December 2020; Published: 14 December 2020 Abstract: Dysmenorrhea is the most common gynecological disorder for women in the reproductive age. Study has indicated that dysmenorrhea might be a general risk factor of chronic pelvic pain and even chronic non-pelvic pain, such as fibromyalgia. We used the Longitudinal Health Insurance Database 2000 from the Taiwan National Health Research Institutes Database to investigate whether women with dysmenorrhea have a higher risk of fibromyalgia and whether treatment of dysmenorrhea reduced the risk of fibromyalgia.
    [Show full text]
  • Supplementary Material Exploring the Efficiency of UHPLC-Orbitrap MS For
    Supplementary Material Exploring the efficiency of UHPLC-Orbitrap MS for the determination of 20 pharmaceuticals and acesulfame K in hospital and urban wastewaters with the aid of FPSE Maria Kalaboka, Christoforos Chrimatopoulos, Cristina Jiménez-Holgado, Vasiliki Boti, Vasilios Sakkas, * and Triantafyllos Albanis University of Ioannina, Chemistry Department, 45110 Ioannina, Greece; [email protected], [email protected] , [email protected], [email protected], talbanis@uoi,gr, [email protected] * Correspondence: [email protected]; Tel.: +30-2651008303 Table S1: Physicochemical properties and chemical structures of target analytes Molecular Therapeutic Compound Chemical Structure pKa [Ref.] logP Formula class - Artificial Acesulfame C4H5NO4S 2.0 [1] 0.552 Sweetener tricyclic Amitriptiline C20H23N 9.4 [2] 4.81 antidepressant s Psychiatric Carbamazepine C15H12N2O 7.0/13.9 [3] 2.766 Antiepileptic Drugs Psychiatric Clomipramine C19H23ClN2 8.98 [4] 4.883 Antidepressant Drugs Psychiatric Cyclobenzaprine C20H21N 8.47 [5] 4.613 Antidepressant Drugs Non-steroidal anti- Diclofenac C14H11Cl2NO2 4.2 [3] 4.259 inflammatory drug (NSAID) Macrolide Erythromycin C37H66NO12 8.9 [3] 2.596 Antibiotic Antidepressant Fluoxetine C17H18F3NO 10.1 [6] 4.173 Drugs Analgesic-anti- Indomethacin C19H16ClNO4 4.27 [3] 3.53 inflammatory drug Nonsteroidal anti- Mefenamic Acid C15H15NO2 4.2 [7] 5.398 inflammatory drugs (NSAID) Psychiatric Paroxetine C19H20O3NF 9.6 [6] 3.148 Antidepressant Drugs Non-steroidal anti- Salicylic acid C7H6O3 2.3/3.5 [6] 1.977 inflammatory drug (NSAID) Sulfonamide Sulfacetamide C8H10N2O3S 5.4 [8] -0.3 Antibiotic Sulfonamide Sulfamethazine C12H14N4O2S 7.6/2.65 [9] 0.65 Antibiotic Sulfonamide Sulfamethoxazole C10H11N3O3S 5.7/1.6 [9] 0.791 Antibiotic Sulfamethoxy- Sulfonamide C11H12N4O3S 6.7 [9] 0.466 pyridazine Antibiotic 6.24/2.
    [Show full text]
  • Migraine Headache Prophylaxis Hien Ha, Pharmd, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas
    Migraine Headache Prophylaxis Hien Ha, PharmD, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas Migraines impose significant health and financial burdens. Approximately 38% of patients with episodic migraines would benefit from preventive therapy, but less than 13% take prophylactic medications. Preventive medication therapy reduces migraine frequency, severity, and headache-related distress. Preventive therapy may also improve quality of life and prevent the progression to chronic migraines. Some indications for preventive therapy include four or more headaches a month, eight or more headache days a month, debilitating headaches, and medication- overuse headaches. Identifying and managing environmental, dietary, and behavioral triggers are useful strategies for preventing migraines. First-line med- ications established as effective based on clinical evidence include divalproex, topiramate, metoprolol, propranolol, and timolol. Medications such as ami- triptyline, venlafaxine, atenolol, and nadolol are probably effective but should be second-line therapy. There is limited evidence for nebivolol, bisoprolol, pindolol, carbamazepine, gabapentin, fluoxetine, nicardipine, verapamil, nimodipine, nifedipine, lisinopril, and candesartan. Acebutolol, oxcarbazepine, lamotrigine, and telmisartan are ineffective. Newer agents target calcitonin gene-related peptide pain transmission in the migraine pain pathway and have recently received approval from the U.S. Food and Drug Administration; ​​​how- ever, more studies of long-term effectiveness and adverse effects are needed. The complementary treatments petasites, feverfew, magnesium, and riboflavin are probably effective. Nonpharmacologic therapies such as relaxation training, thermal biofeedback combined with relaxation training, electromyographic feedback, and cognitive behavior therapy also have good evidence to support their use in migraine prevention. (Am Fam Physician. 2019; 99(1):17-24.
    [Show full text]
  • Effects of the Menstrual Cycle on Medical Disorders
    REVIEW ARTICLE Effects of the Menstrual Cycle on Medical Disorders Allison M. Case, MD; Robert L. Reid, MD xacerbation of certain medical conditions at specific phases of the menstrual cycle is a well-recognized phenomenon. We review the effects of the menstrual cycle on medical conditions, including menstrual migraine, epilepsy, asthma, rheumatoid arthritis, irritable bowel syndrome, and diabetes. We discuss the role of medical suppression of ovulationE using gonadotropin-releasing hormone agonists in the evaluation and treatment of these disorders. Peer-reviewed publications from English-language literature were located via MEDLINE or from bibliographies of relevant articles. We reviewed all review articles, case reports and series, and therapeutic trials. Emphasis was placed on diagnosis and therapy of menstrual cycle– related exacerbations of disease processes. Abrupt changes in the concentrations of circulating ovar- ian steroids at ovulation and premenstrually may account for menstrual cycle–related changes in these chronic conditions. Accurate documentation of symptoms on a menstrual calendar allows identification of women with cyclic alterations in disease activity. Medical suppression of ovula- tion using gonadotropin-releasing hormone agonists can be useful for both diagnosis and treat- ment of any severe, recurrent menstrual cycle–related disease exacerbations. Arch Intern Med. 1998;158:1405-1412 The menstrual cycle, an event that punctu- Several theories have been proposed to ates the lives of most women, may be asso- explain these menstrual cycle–related effects ciated with diverse physical, psychological, on existing disease processes, including fluc- and behavioral changes. Not surprisingly, it tuations in levels of sex steroids, cyclic alter- plays a significant role in women’s health and ations in the immune system, and changing disease.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr
    USOO6221377B1 (12) United States Patent (10) Patent No.: US 6,221,377 B1 Meyer (45) Date of Patent: Apr. 24, 2001 (54) ADMINISTRATION MEDIA FOR (56) References Cited ANALGESIC, ANTI-INFLAMMATORY AND ANT-PYRETC DRUGS CONTAINING FOREIGN PATENT DOCUMENTS NITROUS OXDE AND PHARMACEUTICAL 2 277 264 10/1994 (GB). COMPOSITIONS CONTAINING SUCH MEDIA AND DRUGS OTHER PUBLICATIONS (75) Inventor: Petrus Johannes Meyer, Randburg Chemical ABstracts AN 1985:464783, Hertz et al., Jan. (ZA) 1985.* Chemical Abstracts AN 1978:44978, Berkowitz et al., Jan. (73) Assignee: Pitmy International N.V., Bonaire 1977.* (NL) International Publication No. WO93/25213, published Dec. 23, 1993. (*) Notice: Subject to any disclaimer, the term of this Mikrochim. Acta, vol. 2, No. 5-6, 1980 pp. 464–474, Stahl patent is extended or adjusted under 35 et al., Extraction of natural Substances using Supercritical U.S.C. 154(b) by 0 days. and liquified gases. (21) Appl. No.: 09/068,543 Reynolds J.E.F. et al., “Martindale', 1989, The Pharmaceu tical Press. (22) PCT Filed: Nov. 13, 1996 Science, vol. 194, No. 4268, 1976, pp. 967–968, Berkowitz (86) PCT No.: PCT/IB96/01366 et al., "Nitrous oxide “analgesia': resemblance to opiate action'. S371 Date: May 13, 1998 Steinegger et al., “Lehrbuch der Pharmakognosie und Phy S 102(e) Date: May 13, 1998 topharmazie', Edition 4, 1988. (87) PCT Pub. No.: WO97/17978 * cited by examiner PCT Pub. Date: May 22, 1997 Primary Examiner Jyothsna Venkat (30) Foreign Application Priority Data ASSistant Examiner-Grace Hsu (74) Attorney, Agent, or Firm-Arent Fox Kintner Plotkin Nov. 13, 1995 (ZA) ...................................................
    [Show full text]
  • Migraine and Tension Headache Guideline
    Migraine and Tension Headache Guideline Major Changes as of May 2021 .................................................................................................................... 2 Medications Not Recommended for Headache Treatment .......................................................................... 2 Background ................................................................................................................................................... 2 Diagnosis Red flag warning signs ........................................................................................................................... 3 Differential diagnosis .............................................................................................................................. 3 Imaging ................................................................................................................................................... 3 Migraine versus tension headache ......................................................................................................... 4 Medication overuse headache ................................................................................................................ 4 Menstruation-related migraine ................................................................................................................ 4 Tension Headache Acute treatment ...................................................................................................................................... 5 Prophylaxis ............................................................................................................................................
    [Show full text]
  • For Headache
    *** Drug Safety Alert *** May 6, 2013, the U.S. Food and Drug Administration (FDA) advised health care professionals and women that the anti-seizure medication valproate sodium and related products, valproic acid and divalproex sodium, are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches. Based on information from a recent study, there is evidence that these medications can cause decreased IQ scores in children whose mothers took them while pregnant. Stronger warnings about use during pregnancy will be added to the drug labels, and valproate’s pregnancy category for migraine use will be changed from "D" (the potential benefit of the drug in pregnant women may be acceptable despite its potential risks) to "X" (the risk of use in pregnant women clearly outweighs any possible benefit of the drug). Valproate products will remain in pregnancy category D for treating epilepsy and manic episodes associated with bipolar disorder. BACKGROUND: Valproate products are approved for the treatment of certain types of epilepsy, the treatment of manic episodes associated with bipolar disorder, and the prevention of migraine headaches. They are also used off-label (for uses not approved by FDA) for other conditions, particularly other psychiatric conditions. This alert is based on the final results of the Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study showing that children exposed to valproate products while their mothers were pregnant had decreased IQs at age 6 compared to children exposed to other anti-epileptic drugs. For additional details, see the Drug Safety Communication Data Summary section. RECOMMENDATION: Valproate products should not be used in pregnant women for prevention of migraine headaches and should be used in pregnant women with epilepsy or bipolar disorder only if other treatments have failed to provide adequate symptom control or are otherwise unacceptable.
    [Show full text]
  • Headaches in Woman
    11 Headaches in Women Randolph W. Evans Women have headaches more commonly than men. The preva- lence of migraine is 18% of women and 6% of men. This gender ratio increases from menarche, peaks at 42 years of age, and then declines. For young women the incidence of migraine with aura peaks between the ages of 12 and 13 (14.1/1,000 person- years), and migraine without aura peaks between the ages of 14 and 17 (18.9/1,000 person-years) (1). Table 11-1 provides the life- time prevalence of various headaches in women and men. Estrogen levels are a key factor in the increased prevalence of migraine in women. Evidence includes the following: migraine prevalence increases at menarche; estrogen withdrawal during menstruation is a common migraine trigger; estrogen administra- tion in oral contraceptives and hormone replacement therapy can trigger migraines; migraines typically decrease during the second and third trimesters of pregnancy, when estrogen levels are high; migraines are common immediately postpartum, with the precipi- tous drop in estrogen levels; and migraines generally improve with physiological menopause. Exactly how changes in estrogen levels influence migraine is not understood. Among numerous effects, fluctuations in estrogen levels can result in changes in prostaglandins and the uterus, prolactin release, opioid regula- tion, and melatonin secretion. These fluctuations can also cause changes in neurotransmitters, including the catecholamines, noradrenaline, serotonin, dopamine, and endorphins (2). This chapter reviews some important headache issues for women, including menstrual migraine, menopause and migraine, oral contraceptive use in migraineurs, and headaches during pregnancy and postpartum. MENSTRUAL MIGRAINE The reported prevalence of menstrual migraine varies from 4% to 73%, depending on the criteria used for the timing of the attack.
    [Show full text]